[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Immunology](https://durgical.com/en/immunology/) › [Immunodeficiencies](https://durgical.com/en/immunology/areas/immunodeficiency/) › HIV-1 vs HIV-2

# HIV-1 vs HIV-2

- Topic

[HIV-2](https://durgical.com/en/microbiology/human-immunodeficiency-virus/) causes the same disease as HIV-1 but more slowly, and tests and drugs made for HIV-1 can miss or fail it.

Updated Nov 19, 2026

## Key points

- HIV-2 lives mainly in West Africa (highest in Guinea-Bissau) and in countries linked to it, such as Portugal and France.
- Lower viral load: less sexual and [mother-to-child transmission](https://durgical.com/en/nursing/preventing-mother-to-child-transmission-of-hiv-syphilis-hepatitis-b-and-chagas-t/), slower CD4 fall, longer asymptomatic phase.
- Screening is the same 4th-generation antigen/antibody test; an HIV-1/HIV-2 differentiation immunoassay tells them apart.
- HIV-1 viral load tests do not measure HIV-2: HIV-2 needs its own RNA test.
- HIV-2 is naturally resistant to [NNRTIs](https://durgical.com/en/pharmacology/classes/non-nucleoside-reverse-transcriptase-inhibitors/) and [enfuvirtide](https://durgical.com/en/pharmacology/enfuvirtide/) and less sensitive to some protease inhibitors; integrase inhibitors and [NRTIs](https://durgical.com/en/pharmacology/classes/nucleoside-nucleotide-reverse-transcriptase-inhibitors/) work.

On this page

- The basics Key points
- What it is
- How to think about it
- Step by step
- HIV-1 vs HIV-2: what changes
- Common traps
- Memory aid

- Clinical Clinical notes
- In the lab

- Study Test yourself

- Connections Connections

## What it is

HIV-1 and HIV-2 are two related retroviruses that infect CD4 T cells and can cause AIDS. HIV-1 causes most infections worldwide; HIV-2 is concentrated in West Africa and in countries with ties to it. HIV-2 keeps a lower viral load, spreads less easily and progresses more slowly, but it needs its own viral load test and does not respond to several HIV-1 drugs.

## How to think about it

Same disease, slower clock. HIV-2 attacks the same CD4 T cells, but with far less virus in the blood, so every clock runs slower: transmission, CD4 loss and the road to AIDS. Two things are not slower but different: tests built for HIV-1 can miss it, and some HIV-1 drugs never work on it.

## Step by step

- Both viruses infect CD4 T cells and, untreated, can deplete them until opportunistic infections appear.
- HIV-2 keeps plasma viral load low or even undetectable in most patients, although it still hides in cells as proviral DNA.
- Less virus in blood and genital fluids means fewer infections passed to partners and babies.
- Less virus also means a slower CD4 fall, a longer symptom-free phase, and fewer people reaching AIDS.
- HIV-2 enzymes and envelope differ: the NNRTI pocket and the enfuvirtide target do not fit, and some protease inhibitors bind less well.
- So an HIV-1 viral load or an NNRTI regimen applied to HIV-2 gives false reassurance or treatment failure.

## HIV-1 vs HIV-2: what changes

| Feature | HIV-1 | HIV-2 |
| --- | --- | --- |
| Where it is found | Worldwide; most HIV infections | West Africa (highest in Guinea-Bissau, around 8% of adults); countries with ties to the region, such as Portugal and France |
| Transmission | Efficient sexual and mother-to-child transmission | Less efficient: sexual transmission 5–9 times and mother-to-child transmission 10–20 times lower than HIV-1 |
| Course without treatment | Most progress to AIDS | Lower viral load, slower CD4 fall, longer asymptomatic phase; only 15–25% progress to AIDS, but those who do get the same opportunistic infections |
| Diagnosis | Antigen/antibody screen, then HIV-1/HIV-2 differentiation immunoassay; HIV-1 RNA test if results disagree | Same screen; the differentiation immunoassay names HIV-2 (or leaves it undifferentiated); confirmation needs HIV-2-specific RNA testing |
| Viral load | Standard HIV-1 RNA tests | HIV-1 tests do not measure it; HIV-2 RNA assays, often specialised or in-house; frequently low or undetectable |
| Drug susceptibility | All main classes active | Naturally resistant to NNRTIs and enfuvirtide; reduced to some protease inhibitors ([atazanavir](https://durgical.com/en/pharmacology/atazanavir/), nelfinavir, tipranavir); [darunavir](https://durgical.com/en/pharmacology/darunavir/), lopinavir and saquinavir active; integrase inhibitors and NRTIs active |

## Clinical notes

- Think of HIV-2 in people from West Africa or with partners from there, and in Portugal- or France-linked patients.
- A person with a positive HIV screen, a low CD4 count and an 'undetectable' HIV-1 viral load without treatment may have HIV-2.
- Where differentiation tests are not available, HIV-2 can be treated by mistake with NNRTI-based regimens that do not work on it.

## In the lab

- Step 1: antigen/antibody immunoassay that detects HIV-1 and HIV-2 [antibodies](https://durgical.com/en/biochemistry/enzymes/immunoglobulins/) and HIV-1 p24 antigen.
- Step 2: if reactive, an immunoassay that differentiates HIV-1 from HIV-2 antibodies.
- Step 3: if step 2 is negative or indeterminate, an HIV-1 nucleic acid test; HIV-2 or undifferentiated results go to HIV-2-specific testing.
- Follow-up: CD4 count plus an HIV-2 RNA viral load, not an HIV-1 assay.

## Common traps

- **An undetectable HIV-1 viral load in HIV-2 means good control**: HIV-1 assays do not measure HIV-2; only an HIV-2 RNA test tells.
- **HIV-2 is harmless**: most people progress slowly, but without treatment some develop AIDS with the same opportunistic infections.
- **Any first-line HIV regimen works for HIV-2**: NNRTIs ([efavirenz](https://durgical.com/en/pharmacology/efavirenz/), [nevirapine](https://durgical.com/en/pharmacology/nevirapine/)) and enfuvirtide never work, and some protease inhibitors are weaker; regimens use NRTIs with an integrase inhibitor or an active protease inhibitor such as darunavir.
- **A reactive screen with a negative HIV-1 differentiation result is a false positive**: it may be HIV-2 or very early HIV-1, so RNA testing comes next.

## Memory aid

HIV-2 is «slow and picky»: slow to [spread](https://durgical.com/en/epidemiology/change-management-making-improvements-stick/) and slow to sicken; picky about tests (its own RNA test) and picky about drugs (no NNRTIs, no enfuvirtide).

## Test yourself

Think of the answer, then tap the question to see it.

## A man from Guinea-Bissau has a reactive HIV screen, a CD4 count that has fallen over years and an undetectable HIV-1 viral load without treatment. What is the likely explanation and the next test?

HIV-2 infection: HIV-1 viral load tests do not measure HIV-2. The differentiation immunoassay and an HIV-2-specific RNA test are next.

## Why is HIV-2 passed on less often, both sexually and from mother to child?

It keeps a much lower viral load in blood and genital fluids, so each exposure carries less virus.

## Which antiretroviral classes do not work against HIV-2, and which are relied on instead?

NNRTIs and the fusion inhibitor enfuvirtide do not work, and some protease inhibitors are weaker; NRTIs with an integrase inhibitor (or an active protease inhibitor such as darunavir) are used.

## Is HIV-2 a benign infection that never needs attention?

No. It progresses more slowly and only a minority reach AIDS, but untreated HIV-2 can still cause AIDS with the same opportunistic infections.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/immunology/hiv-1-vs-hiv-2/)

## Connections

## Related 3

- [Secondary immunodeficiency: HIV, malnutrition, drugs, asplenia](https://durgical.com/en/immunology/secondary-immunodeficiency-hiv-malnutrition-drugs-asplenia/)
- [CD4⁺ helper T cell](https://durgical.com/en/immunology/cd4-helper-t-cell/)
- [Immunodeficiency: warning signs and the infection pattern by defect](https://durgical.com/en/immunology/immunodeficiency-warning-signs-and-the-infection-pattern-by-defect/)

## Related conditions 1

- [HIV infection and AIDS](https://durgical.com/en/conditions/hiv-infection-and-aids/)

## Microorganisms 1

- [Human immunodeficiency virus](https://durgical.com/en/microbiology/human-immunodeficiency-virus/)

## In Pharmacology 5

- [Non-nucleoside reverse transcriptase inhibitors (NNRTIs)](https://durgical.com/en/pharmacology/classes/non-nucleoside-reverse-transcriptase-inhibitors/)
- [Enfuvirtide](https://durgical.com/en/pharmacology/enfuvirtide/)
- [HIV protease inhibitors (PIs)](https://durgical.com/en/pharmacology/classes/hiv-protease-inhibitors/)
- [Integrase strand transfer inhibitors (INSTIs)](https://durgical.com/en/pharmacology/classes/integrase-strand-transfer-inhibitors/)
- [Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)](https://durgical.com/en/pharmacology/classes/nucleoside-nucleotide-reverse-transcriptase-inhibitors/)

[← All of immunology](https://durgical.com/en/immunology/)

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: [Human Immunodeficiency Virus Type 2: The Neglected Threat](https://pmc.ncbi.nlm.nih.gov/articles/PMC8621479/) (Pathogens (Ceccarelli G et al.), via PubMed Central, 2021); [Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds](https://pmc.ncbi.nlm.nih.gov/articles/PMC10053740/) (International Journal of Molecular Sciences (Moranguinho I et al.), via PubMed Central, 2023); [Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations](https://stacks.cdc.gov/view/cdc/23447) (Centers for Disease Control and Prevention (CDC) and Association of Public Health Laboratories, 2014).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/immunology/hiv-1-vs-hiv-2/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/immunology/hiv-1-vs-hiv-2/
